Mednet Logo
HomeNeurology
Neurology

Neurology

Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.

Recent Discussions

How do you navigate C-2 refills in patients who are stable in their treatment and do not otherwise need to be clinically seen monthly?

4
7 Answers

Mednet Member
Mednet Member
Psychiatry

This practice is routine in child psychiatry. We fill stimulant prescriptions electronically at the phone request of the family as long as they are keeping quarterly appointments. We do not charge for that service. We do document it in the medical record. Your question begs another question, however...

What is your approach for LINAC based radiosurgery when dealing with benign perioptic lesions very close to the optics apparatus?

7
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

It all starts with the consideration of what I consider an effective dose of SRS or SRT (hypo-fractionated SRS). The minimum effective dose to achieve local control of a metastatic lesion is usually 18 Gy for single fraction, 27 Gy for 3 fractions, and 30 Gy in 5 fractions.I then consider the histol...

Are there any contraindications using nurtec in patients with headaches in the setting of recent RCVS?

1
1 Answers

Mednet Member
Mednet Member
Neurology · UPMC

I would be comfortable using Nurtec in a patient with a recent RCVS diagnosis. I am comfortable using triptans in patients with a prior stroke or MI with proper patient counseling unless they have critical/severe artery stenosis. I have had cluster headache patients who continue sumatriptan injectio...

How do you make the decision to empirically treat for GCA when a patient is referred but cannot be immediately seen in clinic?

4
4 Answers

Mednet Member
Mednet Member
Rheumatology · Massachusetts General Hospital

This is an important question because referrals for possible GCA are common scenarios when a rheumatologist may be asked to recommend a treatment before seeing the patient which are often challenging scenarior. The factors I typically rely on to rate the probability of GCA include: - Specific sympto...

Do you make any dose adjustments for patients with ESKD who are on apixaban and do not otherwise meet criteria for reduced dosing?

1
3 Answers

Mednet Member
Mednet Member
Nephrology · University Of California San Francisco Medical Center At Parnassus

I do most of the time but it depends on the indication and patient's weight and age. For soft indications, I usually give 2.5 mg bid, but if there is a significant risk (stroke, clots, etc), I will give a full dose of 5 mg bid.

When should patients be referred for advanced MRI testing to assess for CVS and PRL?

3 Answers

Mednet Member
Mednet Member
Neurology · Unc Institute For Global Health And Infectious Diseases

There are many pathways to an MS diagnosis that do not rely on CVS or PRL. As such, I think it is very reasonable to start with a standard brain MRI that we have been using for many years for MS diagnosis. Many patients - maybe most - will meet criteria with a standard MRI and, potentially, CSF evid...

What MRI findings would you consider compatible with an acute seizure or seizures?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Memorial Sloan Kettering Cancer Center

Frequent seizures and status epilepticus can result in reversible neuroimaging findings such as cortical enhancement, DWI cortical ribboning, and decreased attenuation on CT. Imaging findings can be resolved with control of seizures.Hormigo et al., PMID 15023812Kramer et al., PMID 3653056Riela et al...

What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

1
2 Answers

Mednet Member
Mednet Member
Neurology · Baylor College of Medicine

All the amyloid antibody trials were conducted in patients without the burden of cerebrovascular disease we often see in clinic populations. Many individuals with cognitive impairment have both vascular and neurogenerative contributions to their decline. We don’t yet know from real-world experience ...

What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?

1
1 Answers

Mednet Member
Mednet Member
Hematology · University of Wisconsin

I strongly advise against routine screening for monoclonal gammopathy in patients with thrombosis. The incidence of MGUS, particularly in older patients, is relatively high and so the signal-to-noise ratio in this setting will be very low. In a patient with recurrent thrombosis and thrombocytopenia ...

How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?

1
1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

Not sure of the current platelet count? Not sure of the age of the patient.Will still use antiplatelet therapy for acute stroke as advised.Support with platelet transfusion as needed for platelet count <20. Hopefully patient responds to HMA and venetoclax, and platelet counts improve.If in CR by mar...